Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database

• DOI: 10.1007/s40120-017-0064-x
• Publication Date: 2017-02-16T10:24:10Z
• Authors: Aaron Boster; Jacqueline Nicholas; Ning Wu; Wei-Shi Yeh; Monica Fay; Michael Edwards; Ming-Yi Huang; Andrew Lee
• Keywords: Teriflunomide; Glatiramer acetate; Dimethyl fumarate; Rate ratio

Limited data are available on the real-world effectiveness of newer oral disease-modifying therapies (DMTs) in multiple sclerosis. The purpose this study was to retrospectively compare dimethyl fumarate (DMF), fingolimod, teriflunomide, and injectable DMTs routine clinical practice based US claims data.Patients newly-initiating DMF, interferon beta (IFNβ), glatiramer acetate (GA), or fingolimod 2013 were identified Truven MarketScan Commercial Claims Databases (N = 6372). Relapse episodes a published claim-based algorithm used determine annualized relapse rate (ARR) for year before after initiating therapy. Poisson negative binomial regression adjusted incidence ratio (IRR) each therapy relative DMF.Significant ARR reductions reported DMF (P < 0.0001). Compared with IRR (95% CI) 1.27 (1.10-1.46) IFNβ, 1.34 (1.17-1.53) GA, 1.23 (1.05-1.45) 1.03 (0.88-1.21) fingolimod. Results consistent across subgroup sensitivity analyses.These suggest have similar demonstrate superior teriflunomide.Biogen, Cambridge, MA, USA.